Fig. 1From: Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthmaClinically significant exacerbation rate/year in adolescent and adult patients in the MENSA and MUSCA trials. Analyses were conducted using a negative binomial regression model including covariates for use of maintenance oral corticosteroids, geographic region, number of exacerbations in the previous year, baseline percentage of the predicted FEV1 (MENSA and MUSCA) and treatment (MENSA only). Increases in 95% CIs observed in adolescent groups are a result of the smaller sample size when compared with ≥ 18 years; CI: confidence interval; FEV1: forced expiratory volume in 1 sBack to article page